Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey

Creative Commons License

Dal M. S., Ulu B. U., UZAY A., Akay O. M., Beşışık S., Yenerel M. N., ...Daha Fazla

Annals of Hematology, cilt.102, sa.1, ss.133-140, 2023 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 102 Sayı: 1
  • Basım Tarihi: 2023
  • Doi Numarası: 10.1007/s00277-022-05052-x
  • Dergi Adı: Annals of Hematology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.133-140
  • Anahtar Kelimeler: Diffuse large B-cell lymphoma, Polatuzumab vedotin, Refractory, Relapsed, Rituximab, Bendamustine, ANTIBODY-DRUG CONJUGATE, NON-HODGKIN-LYMPHOMA, PLUS BENDAMUSTINE, SURVIVAL, SAFETY
  • Kayseri Üniversitesi Adresli: Hayır

Özet

© 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.Polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We analyzed the data of 71 R/R DLBCL patients who had been treated with Pola-BR in the named patient program from March 2018 to April 2021 from 32 centers in Turkey. All patients received up to six cycles of Pola 1.8 mg/kg, rituximab 375 mg/m2 on day 1, and bendamustine 90 mg/m2 on days 1–2 of each cycle. Median age at Pola-BR initiation was 55 (19–84). The overall response rate was 47.9%, including 32.4% CR rate when a median of 3 cycles was applied. With a median follow-up of 5 months, the median OS was 5 months. Grade 3–4 neutropenia and thrombocytopenia were the most common hematological toxicities. The real-world data from our cohort showed the Pola-BR is an effective option with a manageable toxicity profile.